ABVC Biopharma Inc
abvcpharma.comHow Do They Make Money?
Partners pay under licensing deals through upfront fees and development or regulatory milestone payments, with royalties tied to licensed-product sales; BioKey earns revenue as it performs development and manufacturing services.
10-K for FY2025, filed Mar 3, 2026Collaborative Revenues — The Company recognizes collaborative revenues generated through collaborative research, development and/or…View ↗
If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in an…View ↗
The former category of milestone payments consists of those triggered by development and regulatory activities in the territories specified…View ↗
Under the collaborative agreement with the collaboration partners, the Company is entitled to receive royalties on sales of products, which…View ↗
Revenues Derived from Research and Development Activities Services (Also known as the Contract Development & Manufacturing Organization…View ↗
$509.6K
-
10-K for FY2025, filed Mar 3, 2026
$509.6K ↗
Who Are Their Customers?
The company expects to license drug and medical-device candidates to large pharmaceutical companies after Phase II trials; strategic partners may market and distribute products after regulatory approval. Define Biotech has exclusive distribution rights for the maitake supplement in China and Taiwan.
10-K for FY2025, filed Mar 3, 2026Upon completing a Phase II trial, ABVC will seek a partner, typically a large pharmaceutical company, to complete a Phase III study and…View ↗
We focus primarily on developing botanical drugs intended to diagnose, cure, mitigate, or treat human diseases. Together with our strategic…View ↗
On December 6, 2021, BioKey entered into a three-year distribution agreement with Define Biotech Co. Ltd. This Taiwan-based pharmaceutical…View ↗
Do Revenues Turn Into Profits?
No. It lost $4.9M in FY2024.
10-K for FY2025, filed Mar 3, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$736.9KView ↗
- ▼ −67% (Loss)
- vs −$2.3M in Q2 FY2025
-
Aug 27, 2026
Distributed BioKey Cayman shares and separated the subsidiary
Shareholders received shares, while ABVC retained a controlling interest in the separate reporting company.
Sources
8-K, filed Aug 27, 2026
On August 21, 2026, ABVC BioPharma, Inc. (the “Company”) completed the previously announced partial legal and structural separation (the…View ↗
-
Jul 2, 2026
Replaced its independent auditor
Sources
8-K, filed Jul 2, 2026
Item 4.01 Changes in Registrant’s Certifying Accountant.View ↗
Flat. Revenue was $509.6K in FY2024, about the same as the $483K of FY2020.
Revenue sources
The older report described minimal revenue from BioKey's CDMO services; the latest report says revenue comes from intellectual-property outlicensing as well as CDMO services.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 3, 2026As of the date of this Report, the Company’s minimal revenue has come from the sale of CDMO services through BioKey. However, the Company’s…View ↗
As of the date of this Report, the Company’s revenue has come from outlicensing our intellectual properties and providing CDMO services.…View ↗
Loading...
